Alice joined us as a PhD candidate through the prestigious Marie Skłodowska-Curie Actions (MSCA) Doctoral Network EFFecT, A European Training Program to Foster the Full Therapeutic Potential of Antisense Technology across Tissues. Within EFFecT, she will focus on ocular antisense oligonucleotides (ASOs) and dive into the development of therapeutics targeting age related macular degeneration (AMD).
Astherna is honored to be part of such an important EU research consortium in the field of ASO based therapeutics. With Alice’s research, we are also proud to announce that we are expanding our pipeline beyond inherited retinal diseases to explore one of the common causes of vision loss, AMD.
Related Posts
